FIGURE 3. PARP inhibition selectively blocks the growth of BRCA2-deficient tumours in vivo.
From the following article:
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Hannah Farmer, Nuala McCabe, Christopher J. Lord, Andrew N. J. Tutt, Damian A. Johnson, Tobias B. Richardson, Manuela Santarosa, Krystyna J. Dillon, Ian Hickson, Charlotte Knights, Niall M. B. Martin, Stephen P. Jackson, Graeme C. M. Smith and Alan Ashworth
Nature 434, 917-921(14 April 2005)
doi:10.1038/nature03445
BRCA2-deficient ES cells or wild-type cells were injected into nude mice. Animals were then treated with either KU0058684 or vehicle. Significant differences in tumour formation were seen between the BRCA2-deficient xenograft/KU0058684 treatment cohort and the BRCA2-deficient xenograft/vehicle treatment cohort (P = 0.03) and also between the BRCA2-deficient xenograft/KU0058684 treatment cohort and the wild-type xenograft/KU0058684 treatment cohort (P = 0.01). Similar data were obtained in an independent experiment. Error bars represent one standard deviation around the mean.
